Louis J. Bont - Infectious Diseases

Author Information

Louis J. Bont is a distinguished figure in the field of Pediatric Immunology and Infectious Diseases, currently affiliated with the University Medical Center Utrecht in the Netherlands. His work is primarily focused on respiratory syncytial virus (RSV) and other infectious diseases, with a particular emphasis on understanding and mitigating their impact on vulnerable populations such as children and the elderly.

Research Contributions

Dr. Louis J. Bont has made significant contributions to the study of respiratory syncytial virus (RSV), particularly in understanding its epidemiology, transmission, and the development of diagnostic tools and vaccines. His recent work includes assessing the performance of rapid molecular tests for RSV in older adults, examining nosocomial RSV-related mortality in young children, and exploring variations in RSV vaccine efficacy trials. Additionally, Dr. Bont has contributed to the broader field of infectious diseases through his research on HIV-1 variants and COVID-19 related health priorities.

Aliases

Dr. Louis J. Bont is also known by several aliases including L.j. Bont, Louis J. Bont, Louis J Bont, L J Bont, L Bont, L. J. Bont, and L. Bont.

Publication and Citation Metrics

Metric	Value
Citation Count	11,702
H-index	55
Paper Count	328
Affiliation	Division of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, P.O. Box 85090, 3508 AB, Utrecht, the Netherlands.

Publications:

Performance Assessment of a Rapid Molecular Respiratory Syncytial Virus Point-of-Care Test: A Prospective Community Study in Older Adults.

DOI: 10.1093/infdis/jiab600

Year: 2022

Nosocomial RSV-related in-hospital mortality in children <5 years: a global case series

DOI: 10.1101/2022.01.10.22268872

Year: 2022

Year-to-year variation in attack rates could result in underpowered RSV vaccine efficacy trials.

DOI: 10.1016/j.jclinepi.2022.02.003

Year: 2022

Recurrent respiratory syncytial virus infection in a CD14 deficient patient.

DOI: 10.1093/infdis/jiac114

Year: 2022

The diagnostic value of nasal microbiota and clinical parameters in a multi-parametric prediction model to differentiate bacterial versus viral infections in lower respiratory tract infections

DOI: 10.1371/journal.pone.0267140

Year: 2022

A highly virulent variant of HIV-1 circulating in the Netherlands

DOI: 10.1126/science.abk1688

Year: 2022

Soluble signal inhibitory receptor on leukocytes-1 is released from activated neutrophils by proteinase 3 cleavage

DOI: 10.1101/2022.03.03.482795

Year: 2022

Global research priorities on COVID-19 for maternal, newborn, child and adolescent health

DOI: 10.7189/jogh.11.04071

Year: 2021

Global Respiratory Syncytial Virus–Related Infant Community Deaths

DOI: 10.1093/cid/ciab528

Year: 2021

Re-emergence of respiratory syncytial virus following the COVID-19 pandemic in the United States: a modeling study

DOI: 10.1101/2021.07.19.21260817

Year: 2021

What are the Challenges in Antimalarial Therapy?

What is the Significance of Structural Protein Mutations?

What is Safety in the Context of Infectious Diseases?

What Measures Can Individuals Take to Protect Themselves from Infectious Diseases?

Why are Drug Targets Important?

What is Artemisinin-based Combination Therapy (ACT)?

What Challenges Exist in Measles Control?

How Do Vaccines Help During Pandemics?

What is Acute Respiratory Distress Syndrome (ARDS)?

What are the Criteria for Eradication?

Partnered Content Networks

Relevant Topics